Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER.
ANCEF IN PLASTIC CONTAINER vs CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1-2 g IV every 8-12 hours; maximum 12 g/day
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic